Activities of Ceftazidime and Avibactam against β-Lactamase-Producing Enterobacteriaceae in a Hollow-Fiber Pharmacodynamic Model
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Activities of Ceftazidime and Avibactam against β-Lactamase-Producing Enterobacteriaceae in a Hollow-Fiber Pharmacodynamic Model
Authors
Keywords
-
Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 58, Issue 6, Pages 3366-3372
Publisher
American Society for Microbiology
Online
2014-04-01
DOI
10.1128/aac.00080-14
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial
- (2013) Christopher Lucasti et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- ComparativeIn VitroandIn VivoEfficacies of Human Simulated Doses of Ceftazidime and Ceftazidime-Avibactam against Pseudomonas aeruginosa
- (2012) Jared L. Crandon et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Novel Modeling Framework To Guide Design of Optimal Dosing Strategies for β-Lactamase Inhibitors
- (2012) Pratik Bhagunde et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroActivity of MK-7655, a Novel β-Lactamase Inhibitor, in Combination with Imipenem against Carbapenem-Resistant Gram-Negative Bacteria
- (2012) Elizabeth B. Hirsch et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study
- (2012) José A. Vazquez et al. CURRENT MEDICAL RESEARCH AND OPINION
- Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia
- (2012) A. E. Muller et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Avibactam is a covalent, reversible, non- -lactam -lactamase inhibitor
- (2012) D. E. Ehmann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pharmacodynamics of β-Lactamase Inhibition by NXL104 in Combination with Ceftaroline: Examining Organisms with Multiple Types of β-Lactamases
- (2011) Arnold Louie et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of NXL104 in Combination with β-Lactams against Genetically Characterized Escherichia coli and Klebsiella pneumoniae Isolates Producing Class A Extended-Spectrum β-Lactamases and Class C β-Lactamases
- (2011) P. R. S. Lagacé-Wiens et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors
- (2011) Ken Coleman CURRENT OPINION IN MICROBIOLOGY
- Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-ProducingEnterobacteriaceae
- (2010) David M. Livermore et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Mechanistic Studies of the Inactivation of TEM-1 and P99 by NXL104, a Novel Non- -Lactam -Lactamase Inhibitor
- (2010) T. Stachyra et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Evaluation of Ceftazidime and NXL104 in Two Murine Models of Infection Due to KPC-ProducingKlebsiella pneumoniae
- (2010) Andrea Endimiani et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters
- (2010) S. Mushtaq et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In Vitro Activity of NXL104 in Combination with -Lactams against Klebsiella pneumoniae Isolates Producing KPC Carbapenemases
- (2009) A. Endimiani et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of the -lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases
- (2009) T. Stachyra et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search